Literature DB >> 10702394

KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors.

M L Lux1, B P Rubin, T L Biase, C J Chen, T Maclure, G Demetri, S Xiao, S Singer, C D Fletcher, J A Fletcher.   

Abstract

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms arising in the gastrointestinal tract. GISTs express the KIT receptor tyrosine kinase, and many cases have activating mutations in the KIT juxtamembrane region. We now report an analysis of KIT cDNA and genomic sequences in eight GISTs that lack juxtamembrane region mutations. Six cases contained heterozygous exon 9 mutations in which six nucleotides, encoding Ala-Tyr, were duplicated. The other two cases contained homozygous exon 13 missense mutations, resulting in substitution of Glu for Lys(642), that were associated with constitutive KIT tyrosine phosphorylation. Sequence analysis of DNAs from nonneoplastic companion tissues revealed that both the exon 9 and exon 13 mutations were somatic. These are the first descriptions, in any tumor, of mutations in KIT exons encoding the C-terminal end of the extracellular domain and the first part of the split kinase domain. These findings indicate that KIT may be activated by mutations in at least three domains-extracellular, juxtamembrane, and kinase-in GISTs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10702394      PMCID: PMC1876850          DOI: 10.1016/S0002-9440(10)64946-2

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  26 in total

1.  Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I.

Authors:  P Y d'Avis; S C Robertson; A N Meyer; W M Bardwell; M K Webster; D J Donoghue
Journal:  Cell Growth Differ       Date:  1998-01

2.  Activating c-kit gene mutations in human germ cell tumors.

Authors:  Q Tian; H F Frierson; G W Krystal; C A Moskaluk
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

3.  Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors.

Authors:  C A Moskaluk; Q Tian; C R Marshall; C A Rumpel; D W Franquemont; H F Frierson
Journal:  Oncogene       Date:  1999-03-11       Impact factor: 9.867

4.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.

Authors:  S Hirota; K Isozaki; Y Moriyama; K Hashimoto; T Nishida; S Ishiguro; K Kawano; M Hanada; A Kurata; M Takeda; G Muhammad Tunio; Y Matsuzawa; Y Kanakura; Y Shinomura; Y Kitamura
Journal:  Science       Date:  1998-01-23       Impact factor: 47.728

5.  Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors.

Authors:  M Taniguchi; T Nishida; S Hirota; K Isozaki; T Ito; T Nomura; H Matsuda; Y Kitamura
Journal:  Cancer Res       Date:  1999-09-01       Impact factor: 12.701

6.  Expression of Kit in neurofibromin-deficient human Schwann cells: role in Schwann cell hyperplasia associated with type 1 neurofibromatosis.

Authors:  A Badache; N Muja; G H De Vries
Journal:  Oncogene       Date:  1998-08-13       Impact factor: 9.867

7.  A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors.

Authors:  M Nakahara; K Isozaki; S Hirota; J Miyagawa; N Hase-Sawada; M Taniguchi; T Nishida; S Kanayama; Y Kitamura; Y Shinomura; Y Matsuzawa
Journal:  Gastroenterology       Date:  1998-11       Impact factor: 22.682

8.  Full activation of MEN2B mutant RET by an additional MEN2A mutation or by ligand GDNF stimulation.

Authors:  I Bongarzone; E Vigano; L Alberti; M G Borrello; B Pasini; A Greco; P Mondellini; D P Smith; B A Ponder; G Romeo; M A Pierotti
Journal:  Oncogene       Date:  1998-05-07       Impact factor: 9.867

9.  KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors.

Authors:  S I Ernst; A E Hubbs; R M Przygodzki; T S Emory; L H Sobin; T J O'Leary
Journal:  Lab Invest       Date:  1998-12       Impact factor: 5.662

10.  Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas.

Authors:  J Lasota; M Jasinski; M Sarlomo-Rikala; M Miettinen
Journal:  Am J Pathol       Date:  1999-01       Impact factor: 4.307

View more
  120 in total

1.  Paediatric mastocytosis.

Authors:  M C Carter; D D Metcalfe
Journal:  Arch Dis Child       Date:  2002-05       Impact factor: 3.791

2.  A novel germline SDHB mutation in a gastrointestinal stromal tumor patient without bona fide features of the Carney-Stratakis dyad.

Authors:  Ricardo Celestino; Jorge Lima; Alexandra Faustino; Valdemar Máximo; António Gouveia; João Vinagre; Paula Soares; José Manuel Lopes
Journal:  Fam Cancer       Date:  2012-06       Impact factor: 2.375

3.  Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases.

Authors:  J Lasota; A Wozniak; M Sarlomo-Rikala; J Rys; R Kordek; A Nassar; L H Sobin; M Miettinen
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

4.  Apparent KIT Ser(715) deletion in GIST mRNA is not detectable in genomic DNA and represents a previously known splice variant of KIT transcript.

Authors:  Jerzy Lasota; Janusz Kopczynski; Mourad Majidi; Markku Miettinen; Maarit Sarlomo-Rikala
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

5.  KIT gene mutations in gastrointestinal stromal tumors: more complex than previously recognized?

Authors:  Jonathan A Fletcher; Christopher D M Fletcher; Brian P Rubin; Leonie K Ashman; Christopher L Corless; Michael C Heinrich
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

6.  Screening of the c-kit gene missense mutation in invasive ductal carcinoma of breast among north Indian population.

Authors:  Syed Rizwan Hussain; Sunil G Babu; Syed Tasleem Raza; Pradyumn Singh; Faisal Ahmed; Hena Naqvi; Farzana Mahdi
Journal:  Mol Biol Rep       Date:  2012-06-24       Impact factor: 2.316

7.  Gastrointestinal stromal tumour: varied presentation of a rare disease.

Authors:  Trevor Bardell; Diederick W Jalink; David J Hurlbut; C Dale Mercer
Journal:  Can J Surg       Date:  2006-08       Impact factor: 2.089

Review 8.  A clinical and biological overview of gastrointestinal stromal tumors.

Authors:  Myrna Candelaria; Jaime de la Garza; Alfonso Duenas-Gonzalez
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

9.  Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.

Authors:  Michael C Heinrich; Kouros Owzar; Christopher L Corless; Donna Hollis; Ernest C Borden; Christopher D M Fletcher; Christopher W Ryan; Margaret von Mehren; Charles D Blanke; Cathryn Rankin; Robert S Benjamin; Vivien H Bramwell; George D Demetri; Monica M Bertagnolli; Jonathan A Fletcher
Journal:  J Clin Oncol       Date:  2008-10-27       Impact factor: 44.544

10.  Surgical debulking of gastrointestinal stromal tumors: is it a reasonable option after second-line treatment with sunitinib?

Authors:  M A Pantaleo; M Di Battista; F Catena; M Astorino; M Saponara; V Di Scioscio; D Santini; G Piazzi; P Castellucci; G Brandi; G Biasco
Journal:  J Cancer Res Clin Oncol       Date:  2008-01-17       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.